Protalix BioTherapeutics (PLX) Competitors $1.10 +0.01 (+0.92%) (As of 09/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PLX vs. URGN, AKBA, KYTX, EPIX, GLUE, ACIU, TCRX, LYEL, ALIM, and RZLTShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include UroGen Pharma (URGN), Akebia Therapeutics (AKBA), Kyverna Therapeutics (KYTX), ESSA Pharma (EPIX), Monte Rosa Therapeutics (GLUE), AC Immune (ACIU), TScan Therapeutics (TCRX), Lyell Immunopharma (LYEL), Alimera Sciences (ALIM), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. UroGen Pharma Akebia Therapeutics Kyverna Therapeutics ESSA Pharma Monte Rosa Therapeutics AC Immune TScan Therapeutics Lyell Immunopharma Alimera Sciences Rezolute Protalix BioTherapeutics (NYSE:PLX) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations. Is PLX or URGN more profitable? Protalix BioTherapeutics has a net margin of -38.62% compared to UroGen Pharma's net margin of -133.61%. UroGen Pharma's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-38.62% -45.15% -16.63% UroGen Pharma -133.61%N/A -53.18% Do analysts rate PLX or URGN? Protalix BioTherapeutics presently has a consensus target price of $10.00, indicating a potential upside of 809.09%. UroGen Pharma has a consensus target price of $48.38, indicating a potential upside of 276.75%. Given Protalix BioTherapeutics' higher probable upside, equities research analysts clearly believe Protalix BioTherapeutics is more favorable than UroGen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00UroGen Pharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in PLX or URGN? 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 5.0% of Protalix BioTherapeutics shares are owned by company insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, PLX or URGN? Protalix BioTherapeutics has higher earnings, but lower revenue than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$65.49M1.24$8.31M$0.0427.50UroGen Pharma$85.01M3.54-$102.24M-$3.40-3.78 Does the media favor PLX or URGN? In the previous week, UroGen Pharma had 5 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 6 mentions for UroGen Pharma and 1 mentions for Protalix BioTherapeutics. UroGen Pharma's average media sentiment score of 0.59 beat Protalix BioTherapeutics' score of 0.00 indicating that UroGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral UroGen Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer PLX or URGN? UroGen Pharma received 355 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 73.62% of users gave UroGen Pharma an outperform vote while only 62.50% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes562.50% Underperform Votes337.50% UroGen PharmaOutperform Votes36073.62% Underperform Votes12926.38% Which has more volatility and risk, PLX or URGN? Protalix BioTherapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. SummaryUroGen Pharma beats Protalix BioTherapeutics on 11 of the 17 factors compared between the two stocks. Ad Porter & CompanyI’m giving you the name of this investment for freeA new pathway to wealth has been laid out for you. It was created by a second-generation immigrant whose family came here legally in the 1980s, without a penny to their name. This man has created a new business model that allows him to make money from products other businesses produce. Watch now. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$80.89M$3.07B$5.51B$19.00BDividend YieldN/A1.96%4.34%3.54%P/E Ratio27.5028.30144.1726.18Price / Sales1.24245.951,690.1415.63Price / Cash7.77148.4036.8419.86Price / Book2.343.884.835.09Net Income$8.31M-$45.56M$115.08M$981.59M7 Day Performance5.77%0.87%4.03%3.59%1 Month Performance13.26%17.13%9.54%3.77%1 Year PerformanceN/A15.02%29.08%15.99% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma4.4183 of 5 stars4.42 / 5 stars$13.04-5.6%$48.38+271.0%-19.3%$305.84M$85.01M-3.84200Positive NewsAKBAAkebia Therapeutics3.7085 of 5 stars3.71 / 5 stars$1.45+0.7%$5.75+296.6%+8.7%$303.91M$174.50M-6.30430Positive NewsGap UpKYTXKyverna Therapeutics1.8928 of 5 stars1.89 / 5 stars$7.04+0.7%$34.40+388.6%N/A$303.53M$7.03M0.0096Short Interest ↓Gap UpEPIXESSA Pharma2.5695 of 5 stars2.57 / 5 stars$6.81-3.5%$16.50+142.3%+155.5%$302.11MN/A-10.8150Gap DownGLUEMonte Rosa Therapeutics1.9654 of 5 stars1.97 / 5 stars$5.96-4.2%$13.75+130.7%-1.5%$301.05M$5.76M-2.3790Short Interest ↑ACIUAC Immune2.8285 of 5 stars2.83 / 5 stars$3.01-1.6%$12.00+298.7%+14.6%$297.69M$15.49M-4.36140Analyst ForecastNews CoveragePositive NewsGap UpTCRXTScan Therapeutics3.0348 of 5 stars3.03 / 5 stars$5.55-2.5%$12.00+116.2%+88.6%$293.39M$12.20M-4.34100Positive NewsLYELLyell Immunopharma2.7926 of 5 stars2.79 / 5 stars$1.15-0.4%$3.50+205.7%-17.8%$291.91M$54,000.00-1.27270Gap UpALIMAlimera Sciences3.2915 of 5 stars3.29 / 5 stars$5.56+0.5%$8.00+43.9%N/A$291.28M$99.68M-3.54150Short Interest ↓RZLTRezolute3.6664 of 5 stars3.67 / 5 stars$5.26+2.3%$10.75+104.4%+221.9%$291.19MN/A-4.6140 Related Companies and Tools Related Companies: UroGen Pharma Alternatives Akebia Therapeutics Alternatives Kyverna Therapeutics Alternatives ESSA Pharma Alternatives Monte Rosa Therapeutics Alternatives AC Immune Alternatives TScan Therapeutics Alternatives Lyell Immunopharma Alternatives Alimera Sciences Alternatives Rezolute Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PLX) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLX Stock Alerts